
|Articles|June 1, 2008
- Pharmaceutical Executive-06-01-2008
- Volume 0
- Issue 0
John Orwin, Genentech
S
Advertisement
ONE TO WATCH:
John Orwin, SVP, Sales and Marketing, BioOncology, Genentech
Orwin learned the landscape of onoclogy while working as senior director of oncology marketing at Alza, and then eventually as the franchise VP at J&J's Tibotec division. In 2005, he headed out to Cali to join Genentech, and was promoted the same year to head sales and marketing of its BioOncology division. And it's a good thing: Orwin was part of the commercial genius that built such heavyweights as Avastin, Herceptin, and Rituxan.
Articles in this issue
about 18 years ago
Mary Szela, Abbottabout 18 years ago
Mightier Than the Swordabout 18 years ago
Keeshia Muhammad, Teva Specialty Pharmaceuticalsabout 18 years ago
Eric Floyd, Cephalonabout 18 years ago
Nancy Phelan, Wyethabout 18 years ago
Tightening the Chainabout 18 years ago
Kurt Graves, Vertexabout 18 years ago
Wendy Niebler, Shireabout 18 years ago
Perfectly ImperfectAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
2
What the Peptide Advisory Vote Actually Means: Q&A with James LaValle
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
Focusing on Asset Acquisition Over Building a Single Platform Technology
5




